Form 4: Broadwood Partners Acquires $3.88 Million in Oncocyte Corp Shares via Private Placement

Broadwood Partners, L.P. acquired 1,315,339 shares of Oncocyte Corp common stock in a private placement for approximately $3.88 million.

Summary

• Broadwood Partners, L.P. acquired 1,315,339 shares of Oncocyte Corp's common stock on October 2, 2024, through a private placement.
• The purchase price was $2.948 per share, totaling $3,877,619.38.
• Following the transaction, Broadwood Partners directly owns 6,244,405 shares.
• Neal C. Bradsher, as President of Broadwood Capital, Inc. (General Partner of Broadwood Partners), may be deemed to beneficially own the reported securities.
• Broadwood Partners also holds warrants to purchase 150,093 shares of common stock, exercisable at $30.6, expiring on April 19, 2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard transaction of share acquisition. The investment by Broadwood Partners could be seen as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• Broadwood Partners' investment signals confidence in Oncocyte Corp's future prospects.

Industry Context

Private placements are a common method for companies to raise capital, especially for smaller or growth-oriented firms like Oncocyte Corp.

Stakeholder Impact

• The acquisition of shares by Broadwood Partners could potentially increase investor confidence in Oncocyte Corp.

Key Dates